Understanding the interaction of an antitumoral platinum(II) 7-azaindolate complex with proteins and DNA

Katia G. Samper, Venancio Rodríguez, Elisabeth Ortega-Carrasco, Sílvia Atrian, Jean Didier Maréchal, Natalia Cutillas, Ana Zamora, Concepción De Haro, Mercè Capdevila, José Ruiz, Òscar Palacios

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

© Springer Science+Business Media New York 2014. The reactivity of the [Pt(dmba)(aza-N1)(dmso)] complex 1, (a potential antitumoral drug with lower IC<inf>50</inf> than cisplatin in several tumoral cell lines) with different proteins and oligonucleotides is investigated by means of mass spectrometry (ESI-TOF MS). The results obtained show a particular binding behaviour of this platinum(II) complex. The interaction of 1 with the assayed proteins apparently takes place by Pt-binding to the most accessible coordinating amino acids, presumably at the surface of the protein -this avoiding protein denaturation or degradation- with the subsequent release of one or two ligands of 1. The specific reactivity of 1 with distinct proteins allows to conclude that the substituted initial ligand (dmso or azaindolate) is indicative of the nature of the protein donor atom finally bound to the platinum(II) centre, i.e. N- or S-donor amino acid. Molecular modeling calculations suggest that the release of the azaindolate ligand is promoted by a proton transfer to the non-coordinating N present in the azaindolate ring, while the release of the dmso ligand is mainly favoured by the binding of a deprotonated Cys. The interaction of complex 1 with DNA takes always place through the release of the azaindolate ligand. Interestingly, the interaction of 1 with DNA only proceeds when the oligonucleotides are annealed forming a double strand. Complex 1 is also capable to displace ethidium bromide from DNA and it also weakly binds to DNA at the minor groove, as shown by Hoechst 33258 displacement experiments. Furthermore, complex 1 is also a good inhibitor of cathepsin B (an enzyme implicated in a number of cancer related events). Therefore, although compound 1 is definitely able to bind proteins that can hamper its arrival to the nuclear target, it should be taken into consideration as a putative anticancer drug due to its strong interaction with oligonucleotides and its effective inhibition of cat B.
Original languageEnglish
Pages (from-to)1159-1177
JournalBioMetals
Volume27
Issue number6
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Antitumoral compound
  • DNA interaction
  • Mass spectrometry
  • Platinum
  • Protein interaction

Fingerprint

Dive into the research topics of 'Understanding the interaction of an antitumoral platinum(II) 7-azaindolate complex with proteins and DNA'. Together they form a unique fingerprint.

Cite this